IgA Vasculitis in the Setting of Biologic Therapy for Psoriasis and Recurrent Cutaneous Methicillin-Resistant Staphylococcus aureus ColonizationOctober 26, 2022PsoriasisPsoriatic ArthritisInfectious Diseases
Medicare Part D Prescription Claims for Brodalumab: Analysis of Annual Trends for 2017-2019October 5, 2022Psoriasis
Optimizing Narrowband UVB Phototherapy: Is It More Challenging for Your Older Patients?September 14, 2022Contact DermatitisAtopic DermatitisPsoriasis
Generalized Pustular Psoriasis: A Review of the Pathophysiology, Clinical Manifestations, Diagnosis, and TreatmentAugust 10, 2022Psoriasis
Management of Psoriasis With Topicals: Applying the 2020 AAD-NPF Guidelines of Care to Clinical PracticeAugust 10, 2022Psoriasis
Guidance From the National Psoriasis Foundation COVID-19 Task ForceAugust 10, 2022PsoriasisCOVID-19 Updates
Cutaneous Body Image: How the Mental Health Benefits of Treating Dermatologic Disease Support Military Readiness in Service MembersJune 14, 2022AcneRosaceaPsoriasis
An Update on JAK Inhibitors in Skin DiseaseMarch 3, 2022Atopic DermatitisPsoriasisPsoriatic Arthritis
Concurrent Atopic Dermatitis and Psoriasis Vulgaris: Implications for Targeted Biologic TherapyFebruary 4, 2022PsoriasisAtopic Dermatitis
Adjunctive Use of Halobetasol Propionate–Tazarotene in Biologic-Experienced Patients With PsoriasisFebruary 4, 2022Psoriasis
